

[For Immediate Release]

The information contained in this document is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This document does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The shares mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended or supplemented from time to time (the "U.S. Securities Act"). The shares mentioned herein may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of securities in the United States. The shares mentioned herein are being offered and sold outside the United States as offshore transactions in accordance with Regulation S under the U.S. Securities Act.

You are cautioned not to place undue reliance on the forward-looking statements contained herein. We can give no assurance that these forward-looking statements will prove to have been correct. Expectations reflected in these forward-looking statements are subject to change and we undertake no obligation to publicly update or revise any forward-looking statements therein.

This document is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for the Company's shares. Potential investors should read the prospectus of the Company dated 30 June 2016 for detailed information about the Company before deciding whether or not to invest in the shares of the Company and should exercise caution when dealing in the Company's shares.



**Vincent Medical Holdings Limited
Announces Details of Proposed Listing on the Main Board of
the Stock Exchange of Hong Kong Limited**

* * * *

**Global Offering of 127,600,000 Shares
Offer Price Ranges from HK\$1.00 to HK\$1.25 Per Share**

(29 June 2016, Hong Kong) — **Vincent Medical Holdings Limited** ("Vincent Medical" or the "**Group**"), the second largest¹ exporter of respiratory and anaesthesia disposables in China and a Hong Kong-headquartered medical device manufacturing company, today announced the details for the proposed listing of its shares on the Main Board of the Stock Exchange of Hong Kong Limited ("SEHK").

Offering Details

The Group intends to offer a total of 127,600,000 shares under the Global Offering (subject to the exercise of the Over-allotment Option), of which 90% will be allocated for the International Placing, and the remaining 10% will be allocated for the Hong Kong Public Offering (subject to adjustment). The indicative Offer Price range is between HK\$1.00 per share to HK\$1.25 per share. After deducting relevant expenses, and assuming an Offer Price of HK\$1.125 per share (being the mid-point of the indicative Offer Price range), the estimated net proceeds of the Global Offering is HK\$111.1 million.

The Hong Kong Public Offering will commence on 30 June 2016 (Thursday), and end at 12:00 noon on 6 July 2016 (Wednesday). The final Offer Price and the results of the allocation are expected to announce on 12 July 2016 (Tuesday). Dealing of the Shares is expected to commence on the Main Board of SEHK on 13 July 2016 (Wednesday) under the stock code 1612. The shares are to be traded in board lots of 2,000 shares.

BOSC International Company Limited is the Sole Sponsor and the Sole Global Coordinator. BOSC International Company Limited, Crosby Securities Limited and Shenwan Hongyuan Capital (H.K.) Limited are the Joint Bookrunners of the listing.

¹ According to the commissioned report prepared by China Insights Consulting Limited ("CIC Report") based on export value in 2015

Investment Highlights

In-depth experience in the production of medical devices with leading position in respiratory and anaesthesia disposables in China

Established in 1997, Vincent Medical is a Hong Kong-headquartered medical devices group and the second largest¹ exporter of respiratory and anaesthesia disposables in China. The Group strives to develop, manufacture and sell a wide range of medical devices, focusing on respiratory products, imaging contrast media power injector (“CMPI”) disposable products and orthopaedic and rehabilitation products, which satisfy internationally recognised quality assurance standards, to its customers in China and overseas markets. The Group has established OEM business since its inception and OBM business in 2003 with its own “Inspired Medical” (“英仕醫療”) brand.

During the Track Record Period, OEM and OBM businesses recorded a CAGR of 17.5% and 17.9% respectively. Sales of respiratory products, imaging CMPI disposable products, orthopaedic and rehabilitation products, and other products represented for 39.1%, 34.7%, 16.5% and 9.7% respectively of the Group’s turnover in FY2015.

Strong OEM capability and strategic cooperation with leading healthcare and medical device companies

OEM business has been the key growth driver of Vincent Medical, accounting for 87% of its total turnover for FY2015, which lays a solid foundation for the Group’s business growth. The Group has developed an international customer base comprising multiple leading international healthcare and medical device companies from the United States, Europe and Japan. In 2015, Vincent Medical served over 70 OEM customers, some of the major OEM customers, including “Bayer Group” and GE Healthcare, have been cooperating with the Group for over 10 years.

As a trusted OEM manufacturer for its product quality, reliability and safety, the Group has started its strategic cooperation with “Bayer Group” since 2000, which holds a 19.9% shareholding in the Group’s subsidiary, VMHK. It is the Group’s largest customer and the OEM customer for its imaging CMPI disposable products. Moreover, “Bayer Group” and another major international medical device company have set up production lines owned by them in the Group’s production facilities for production of their products, demonstrating the trust in Vincent Medical as an approved supplier. All these achievements are believed to develop a solid foundation for the Group’s business development and long term growth.

Established “Inspired Medical” (“英仕醫療”) brand with domestic and overseas distributorship network for expansion of OBM Business

Currently, Vincent Medical offers 11 categories of OBM products under its established own “Inspired Medical” (“英仕醫療”) brand, meeting international quality standards at more competitive prices to its OBM customers. Over the years, the Group has formed a domestic distributorship network with over 380 distributors and other customers, covering approximately 360 hospitals in 28 provinces and regions in China in 2015. Meanwhile, an overseas distributorship network was established with 42 overseas distributors and other customers in various countries such as Australia, Japan, Korea, Indonesia, India, Chile, Brazil and Saudi Arabia in 2015. The established distributorship platform allows Vincent Medical to further expand its OBM business in China and overseas markets.

The Group has also set up a product research and development team with initiatives to enhance its OBM products’ quality and functionality, carry out in-house research, and collaborate with its research partners in some research and development projects so as to addressing patients’ needs and market demand.

Proven track record in obtaining medical device validation, certification and registration and placing strong focus on stringent quality assurance and cost efficiency

With over 19 years of operating history, Vincent Medical has attained substantial expertise and efficiency in the production processes for medical devices, satisfying internationally recognised quality assurance standards. Backed in 2009, Vincent Medical was the first Hong Kong-headquartered medical device group to have obtained the ISO14971 certification for the application of risk management to medical devices. The Group is also experienced in product validation, certification and registration for sales of medical devices in China and overseas such as European Union, the United States, Canada, Japan and Australia. Its quality assurance department is familiar with requirements and processes in obtaining various registration, certification or approvals, which enables the Group to roll out its new products efficiently in the future.

Strong emphasis has also been placed on the Group's stringent quality assurance processes in its production facilities for medical devices in Dongguan, China. Equipped with specialised facilities such as Class 100,000 clean rooms for injection, blow moulding, extrusion and assembling of its products, and also two certified EtO sterilisation systems imported from the United States and France for the sterilisation of medical devices, coupling with the Group's quality management system in accordance with the applicable regulations and standards.

While maintaining stringent quality control over its products, the Group strives to achieve an efficient cost structure through the redesigning of production processes, selection of raw materials, and automation of processes to improve efficiency, and an experienced and well-trained work force, in order to lower its material, labour and overhead costs and to compete favourably with competitors based in developed countries with higher production costs. In addition, as the Group normally takes orders with large production volume, the resulting economies of scale enables the Group to enjoy significant bargaining power in order to minimise costs and enhance procurement efficiency.

Experienced and dedicated management team with solid financial performance

The Group has an experienced and dedicated management team, led by Mr. Vincent Choi, Founder, Chairman and Executive Director, and Mr. Otto To, Chief Executive Officer and Executive Director, who have been instrumental in spearheading the growth of the Group. Mr. Choi and Mr. To have over 37 and 20 years of relevant working experiences in the industry respectively. Over the years, the management team has built close relationships with the Group's customers and suppliers, accumulated in-depth knowledge of the medical device industry and stayed abreast of industry development and market trends. This has enabled the management team to provide invaluable recommendations regarding the Group's business strategy and development, bringing strategic gains to Vincent Medical.

Growth Strategies

According to the CIC report, market demand for respiratory and anaesthesia disposables, imaging CMPI disposable products and orthopaedic and rehabilitation products is increasing continuously, of which the overall revenue from respiratory and anaesthesia disposables in the global and China markets is expected to grow by a CAGR of 9.1% and 9.6% from 2015 to 2020 respectively, showing the huge growth potential of the industry. To capture the immense opportunities in both global and China's medical device industry, Vincent Medical will implement a two-pronged strategy to realise business growth.

The Group will expand OBM business by enhancing its product offering through its in-house research and development, and collaboration with research partners such as Guangzhou Institute of Respiratory Disease, Ventific and 12th Man Technologies. In 2015, the Group has acquired a 53.125% interest in Rehab-Robotic Company Limited, the developer of the "Hand of Hope", an EMG-driven robotic hand training device for stroke patients, which has won the Grand Prix Award in the 2012 International Exhibition of Inventions of Geneva. A series of new and pipeline products are expected to launch in between 2016 and 2018. OBM distributorship network and sales and marketing efforts will also be strengthened for achieving further OBM business growth. As for the expansion of OEM business, the Group intends to enhance its capability by engaging in additional production projects for existing OEM customers and providing value-added services for overseas customers in assisting them to apply for CFDA registration for sales in China. On the operation front, the Group will also expand and upgrade production facilities to achieve greater efficiency and increase capacity. With the clear business expansion plan in place, Vincent Medical is well positioned to seize the business opportunities in the growing medical device industry.

Use of Proceeds

Assuming an Offer Price of HK\$1.125 per share (being the mid-point of the indicative Offer Price range), the estimated net proceeds of the global offering is HK\$111.1 million intended for the following uses:

Item	Percentage
• Investment in the expansion and upgrading of production facility	50.0%
• Development of new and pipeline products	27.0%
• Investment in sales and marketing	18.0%
• General corporate purposes and working capital	5.0%

Financial Performance

HK\$'000	For the year ended 31 December			
	2013	2014	2015	CAGR
Turnover	324,492	388,977	448,169	17.5%
Gross profit	88,199	115,064	139,801	25.9%
Gross profit margin (%)	27.2	29.6	31.2	N/A
Net profit attributable to owners	23,413	35,759	52,594*	49.9%
Net profit margin attributable to owners (%)	7.2	9.2	11.7	N/A

*After the deduction of the over-provision of taxes in prior years and adding back the listing expenses

- End -

About Vincent Medical Holdings Limited (永勝醫療控股有限公司)

Established in 1997, Vincent Medical Holdings Limited is a Hong Kong-headquartered medical device manufacturing company. The Group develops, manufactures and sells a wide range of medical devices, focusing on respiratory products, imaging contrast media power injector disposable products, and orthopaedic and rehabilitation products, which satisfy internationally recognised quality assurance standards, to its customers in China and overseas markets. The Group has established its OEM business since its inception and OBM business in 2003 with its "Inspired Medical" ("英仕醫療") brand. According to the CIC Report, Vincent Medical was the second largest exporter of respiratory and anaesthesia disposables in China based on export value in 2015. The Group has developed a domestic and overseas distributorship network for its OBM business, which has over 380 distributors and other customers in China in 2015, and 42 overseas distributors and other customers in various countries such as Australia, Japan, Korea, Indonesia, India, Chile, Brazil and Saudi Arabia in 2015.

For media enquiries, please contact: Strategic Financial Relations Limited

Joanne Lam Tel: (852) 2864 4816
Katrina Leung Tel: (852) 2864 4857
Cecilia Shum Tel: (852) 2864 4890
Fax: (852) 2527 1196

Email: joanne.lam@sprg.com.hk
Email: katrina.leung@sprg.com.hk
Email: cecilia.shum@sprg.com.hk